Becton Dickinson (BDX) EVP sells 75 shares in open-market trade

Rhea-AI Filing Summary

Becton Dickinson & Co EVP and Chief Revenue Officer Michael Feld sold 75 shares of common stock in an open-market transaction at $181.84 per share. After this sale, he directly holds 21,308 shares. A footnote notes prior adjustments to his direct holdings tied to the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Feld Michael

(Last) (First) (Middle)

C/O BECTON, DICKINSON AND COMPANY

1 BECTON DRIVE

(Street)

FRANKLIN LAKES NJ 07417

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BECTON DICKINSON & CO [ BDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Revenue Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2026		S		75	D	$181.84	21,308(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Direct holdings reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of shares underlying previously reported and unvested time-vested restricted stock units held by the reporting person.

Remarks:

This reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 7, 2025.

	Donna Kalazdy, by power of attorney from Michael Feld	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BDX executive Michael Feld report on Form 4?

Michael Feld, EVP and Chief Revenue Officer of Becton Dickinson, reported selling 75 shares of common stock in an open-market transaction at $181.84 per share. Following this sale, his direct ownership stands at 21,308 shares.

How many Becton Dickinson (BDX) shares did Michael Feld sell and at what price?

Michael Feld sold 75 shares of Becton Dickinson common stock at a price of $181.84 per share. The transaction was reported as an open-market sale and is classified as a non-derivative transaction on the Form 4.

How many BDX shares does Michael Feld own after this Form 4 transaction?

After the reported sale, Michael Feld directly holds 21,308 shares of Becton Dickinson common stock. This post-transaction balance reflects his remaining direct ownership as disclosed in the Form 4 filing data.

What is Michael Feld’s role at Becton Dickinson (BDX) in this Form 4 filing?

In the Form 4, Michael Feld is identified as an officer of Becton Dickinson, serving as Executive Vice President and Chief Revenue Officer. He is not reported as a director or a ten percent owner in this filing.

Was the BDX insider transaction by Michael Feld a buy or a sell?

The transaction reported by Michael Feld was a sell. The Form 4 classifies it as an open-market sale of 75 shares of Becton Dickinson common stock, using transaction code “S” for a sale in open market or private transaction.

What does the Form 4 footnote say about Michael Feld’s BDX share holdings?

The footnote explains that Feld’s direct holdings reflect adjustments made in connection with combining the Biosciences and Diagnostic Solutions businesses with Waters Corp., affecting the number of shares underlying his previously reported, unvested time-vested restricted stock units.